Therefore, tumor metastasis accompanied by metabolic alterations and further metabolic pathways analysis of SETD2 inactivated in ccRCC will have the potential to discover new therapeutics for precision medicine. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.